Immunobiologicals in Psoriasis at HUOL, UFRN, Natal, RN: Evaluation of Therapeutic Results with Immunobiologicals in Severe Psoriasis at UFRN

Psoriasis is a chronic, immune-mediated, multifactorial inflammatory disease that may be associated with comorbidities and interfere with quality of life. The patients included in the study were treated with immunobiological agents from March 2008 to March 2015. Of the patients studied, 17 started treatment with Adalimumab, 15 with Infliximab, and 5 with Etanercept. The results showed that 37 patients (60.7%) controlled their psoriasis with a single immunobiological agent; 15 patients (24.6%) with a second immunobiological agent; 6 patients (9.8%) with a third immunobiological agent; and only 3 patients (4.9%) needed to use a fourth immunobiological agent, Ustekinumab, to achieve an effective therapeutic response. Immunobiologicals represent an important therapeutic resource for severe forms of psoriasis. In conclusion, excellent therapeutic results were observed in all patients, with few adverse effects and a high rate of adherence to treatment, providing them with personal rehabilitation and family, social, and professional reintegration. Read more